The Metals Company Announces Fourth Quarter 2022 Corporate Update Conference Call for Thursday, March 23, 2023 15-03-2023, 20:37

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Construction Begins on Hydrogen-Based Ironmaking Plant in Linz, Austria 25-09-2025, 19:25